4D Molecular Therapeutics, Inc. (FDMT)
FDMT Stock Price Chart
Explore 4D Molecular Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze FDMT price movements and trends.
FDMT Company Profile
Discover essential business fundamentals and corporate details for 4D Molecular Therapeutics, Inc. (FDMT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Dec 2020
Employees
227.00
CEO
David H. Kirn
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
FDMT Financial Timeline
Browse a chronological timeline of 4D Molecular Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 26 Feb 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$1.02, while revenue estimate is $403.00K.
Earnings released on 11 Aug 2025
EPS came in at -$0.98 falling short of the estimated -$0.88 by -11.36%, while revenue for the quarter reached $15.00K , beating expectations by +221.20%.
Earnings released on 8 May 2025
EPS came in at -$0.86 falling short of the estimated -$0.84 by -2.38%, while revenue for the quarter reached $14.00K , missing expectations by -97.40%.
Earnings released on 28 Feb 2025
EPS came in at -$0.90 falling short of the estimated -$0.80 by -12.50%, while revenue for the quarter reached $1.00K , missing expectations by -99.96%.
Earnings released on 13 Nov 2024
EPS came in at -$0.79 falling short of the estimated -$0.67 by -17.91%, while revenue for the quarter reached $3.00K , missing expectations by -99.86%.
Earnings released on 8 Aug 2024
EPS came in at -$0.63 surpassing the estimated -$0.72 by +12.50%, while revenue for the quarter reached $5.00K , missing expectations by -99.62%.
Earnings released on 9 May 2024
EPS came in at -$0.66 surpassing the estimated -$0.73 by +9.59%, while revenue for the quarter reached $28.00K , missing expectations by -96.41%.
Earnings released on 29 Feb 2024
EPS came in at -$0.77 falling short of the estimated -$0.68 by -13.24%, while revenue for the quarter reached -$19.00K , missing expectations by -100.79%.
Earnings released on 9 Nov 2023
EPS came in at -$0.24 surpassing the estimated -$0.67 by +64.18%, while revenue for the quarter reached $20.20M , beating expectations by +880.78%.
Earnings released on 9 Aug 2023
EPS came in at -$0.77 matching the estimated -$0.77, while revenue for the quarter reached $239.00K , missing expectations by -71.88%.
Earnings released on 10 May 2023
EPS came in at -$0.88 matching the estimated -$0.88, while revenue for the quarter reached $298.00K , missing expectations by -71.07%.
Earnings released on 15 Mar 2023
EPS came in at -$0.84 falling short of the estimated -$0.75 by -12.00%, while revenue for the quarter reached $1.25M , missing expectations by -58.57%.
Earnings released on 8 Nov 2022
EPS came in at -$0.79 surpassing the estimated -$0.85 by +7.06%, while revenue for the quarter reached $500.00K , beating expectations by +32.89%.
Earnings released on 11 Aug 2022
EPS came in at -$0.87 falling short of the estimated -$0.78 by -11.54%, while revenue for the quarter reached $162.00K , missing expectations by -81.07%.
Earnings released on 12 May 2022
EPS came in at -$0.82 falling short of the estimated -$0.73 by -12.33%, while revenue for the quarter reached $1.22M , beating expectations by +60.75%.
Earnings released on 28 Mar 2022
EPS came in at -$0.85 falling short of the estimated -$0.82 by -3.66%, while revenue for the quarter reached $92.00K , missing expectations by -89.78%.
Earnings released on 10 Nov 2021
EPS came in at -$0.82 surpassing the estimated -$0.83 by +1.20%, while revenue for the quarter reached $1.37M , missing expectations by -1.19%.
Earnings released on 12 Aug 2021
EPS came in at -$0.28 surpassing the estimated -$0.71 by +60.56%, while revenue for the quarter reached $14.58M , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$0.61 surpassing the estimated -$1.10 by +44.55%, while revenue for the quarter reached $2.00M , missing expectations by -23.13%.
Earnings released on 25 Mar 2021
EPS came in at -$2.36 falling short of the estimated -$0.66 by -257.58%, while revenue for the quarter reached -$977.00K .
Earnings released on 16 Dec 2020
EPS came in at -$1.02 , while revenue for the quarter reached $3.63M .
Earnings released on 30 Sept 2020
EPS came in at -$0.36 , while revenue for the quarter reached $7.42M .
FDMT Stock Performance
Access detailed FDMT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.